Literature DB >> 26405165

Harnessing the Power of Molecular Imaging for Precision Medicine.

Emily B Ehlerding1, Weibo Cai2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26405165      PMCID： PMC4738016          DOI： 10.2967/jnumed.115.166199

Source DB:  PubMed          Journal:  J Nucl Med        ISSN： 0161-5505            Impact factor:   10.057


× No keyword cloud information.
  14 in total

Review 1.  A tabulated summary of the FDG PET literature.

Authors:  S S Gambhir; J Czernin; J Schwimmer; D H Silverman; R E Coleman; M E Phelps
Journal:  J Nucl Med       Date:  2001-05       Impact factor: 10.057

Review 2.  Development of RGD-based radiotracers for tumor imaging and therapy: translating from bench to bedside.

Authors:  Z Liu; F Wang
Journal:  Curr Mol Med       Date:  2013-12       Impact factor: 2.222

Review 3.  An evidence-based review of quantitative SPECT imaging and potential clinical applications.

Authors:  Dale L Bailey; Kathy P Willowson
Journal:  J Nucl Med       Date:  2013-01       Impact factor: 10.057

4.  VEGF-integrin interplay controls tumor growth and vascularization.

Authors:  Sarmishtha De; Olga Razorenova; Noel Patrick McCabe; Timothy O'Toole; Jun Qin; Tatiana V Byzova
Journal:  Proc Natl Acad Sci U S A       Date:  2005-05-16       Impact factor: 11.205

5.  99mTc-3PRGD2 for integrin receptor imaging of lung cancer: a multicenter study.

Authors:  Zhaohui Zhu; Weibing Miao; Qianwei Li; Haojie Dai; Qingjie Ma; Feng Wang; Aiming Yang; Bing Jia; Xiaona Jing; Sha Liu; Jiyun Shi; Zhaofei Liu; Zhoushe Zhao; Fan Wang; Fang Li
Journal:  J Nucl Med       Date:  2012-04-12       Impact factor: 10.057

6.  Molecular Imaging of Post-Src Inhibition Tumor Signatures for Guiding Dasatinib Combination Therapy.

Authors:  Liquan Gao; Hao Liu; Xianlei Sun; Duo Gao; Chenran Zhang; Bing Jia; Zhaohui Zhu; Fan Wang; Zhaofei Liu
Journal:  J Nucl Med       Date:  2015-09-17       Impact factor: 10.057

7.  Overriding imatinib resistance with a novel ABL kinase inhibitor.

Authors:  Neil P Shah; Chris Tran; Francis Y Lee; Ping Chen; Derek Norris; Charles L Sawyers
Journal:  Science       Date:  2004-07-16       Impact factor: 47.728

8.  First experience of 18F-alfatide in lung cancer patients using a new lyophilized kit for rapid radiofluorination.

Authors:  Weixing Wan; Ning Guo; Donghui Pan; Chunjing Yu; Yuan Weng; Shineng Luo; Hong Ding; Yuping Xu; Lizhen Wang; Lixin Lang; Qingguo Xie; Min Yang; Xiaoyuan Chen
Journal:  J Nucl Med       Date:  2013-04-03       Impact factor: 10.057

Review 9.  A molecular imaging primer: modalities, imaging agents, and applications.

Authors:  Michelle L James; Sanjiv S Gambhir
Journal:  Physiol Rev       Date:  2012-04       Impact factor: 37.312

10.  Application of (68)Ga-PRGD2 PET/CT for αvβ3-integrin imaging of myocardial infarction and stroke.

Authors:  Yi Sun; Yong Zeng; Yicheng Zhu; Feng Feng; Weihai Xu; Chenxi Wu; Bing Xing; Weihong Zhang; Peiling Wu; Liying Cui; Renzhi Wang; Fang Li; Xiaoyuan Chen; Zhaohui Zhu
Journal:  Theranostics       Date:  2014-05-25       Impact factor: 11.556
View more
  4 in total

Review 1.  Molecular imaging of β-cells: diabetes and beyond.

Authors:  Weijun Wei; Emily B Ehlerding; Xiaoli Lan; Quan-Yong Luo; Weibo Cai
Journal:  Adv Drug Deliv Rev       Date:  2018-07-03       Impact factor: 15.470

2.  Precision medicine and molecular imaging: new targeted approaches toward cancer therapeutic and diagnosis.

Authors:  Mojtaba Ghasemi; Iraj Nabipour; Abdolmajid Omrani; Zeinab Alipour; Majid Assadi
Journal:  Am J Nucl Med Mol Imaging       Date:  2016-11-30

Review 3.  Preclinical Molecular Imaging for Precision Medicine in Breast Cancer Mouse Models.

Authors:  M F Fiordelisi; L Auletta; L Meomartino; L Basso; G Fatone; M Salvatore; M Mancini; A Greco
Journal:  Contrast Media Mol Imaging       Date:  2019-09-22       Impact factor: 3.161

4.  "Albumin Hitchhiking" with an Evans Blue Analog for Cancer Theranostics.

Authors:  Emily B Ehlerding; Xiaoli Lan; Weibo Cai
Journal:  Theranostics       Date:  2018-01-01       Impact factor: 11.556
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.